|
| Pfizer announced the M&A event of the year with its Biohaven acquisition. Top investors turned to Tegus for on-demand insight on Nurtec’s trajectory, Biohaven’s leadership, and the competitive environment. See for yourself with a free Tegus trial. |
BridgeBio's CEO on staying alive, 'motherhood and apple pie' Servier's Tibsovo snags FDA combo nod in first-line AML, expanding its use in tough-to-treat cancer Pharmacy groups pressure FTC to ramp up scrutiny and enforcement of PBMs Roche rolls out trio of PCR research tests for monkeypox With the right partner, Pfizer gains fast-track tag for previously shelved NASH drug J&J debuts rap video, enlists Bollywood star to recruit young people for India's TB fight HHS withdraws controversial Trump-era sunset rule that required review of all regulations Medtronic joins forces with DaVita to launch new kidney tech company IN-ACTIV: NRx tanks as peptide fails NIH trial in severe COVID-19 patients Healthcare leaders urge Congress to make Texas school shooting the country's last: 'We need real change' Sanofi, Regeneron's Libtayo scores UK watchdog's approval in common form of skin cancer Biotech co-founder arrested on murder-for-hire charges Featured Story | By Gabrielle Masson It’s survival of the fittest, and BridgeBio Pharma is cutting fat—shedding any and all extra costs in an attempts to stay afloat in a prolonged bear market. CEO Neil Kumar, Ph.D., hopes the industry will take notes to ultimately embolden a better biotech frontier. read more |
| |
|---|
|
Top Stories By Kevin Dunleavy Approved three years ago as a solo agent for certain patients with IDH1-mutated acute myeloid leukemia, Servier’s Tibsovo has now scored a wider indication as the company works to expand its use. The blessing is further evidence that Servier made a smart buy last April when it acquired Agios Pharma’s oncology assets—led by Tibsovo—for $1.8 billion. read more By Robert King Pharmacy groups are pressing the FTC to scrutinize several contracting practices initiated by PBMs, including claw back fees and steering patients towards PBM-affiliated facilities. read more By Andrea Park If there’s one positive outcome of the COVID-19 pandemic, it’s the speed at which diagnostic test makers learned to develop and begin churning out kits to test for a virus. read more By Annalee Armstrong In a rare win for the difficult field of nonalcoholic steatohepatitis, Pfizer has been granted a fast-track ticket for two experimental therapies. read more By Natalie Missakian Janssen India is looking to the younger generation to help fight the country's TB epidemic with assistance from a famous Bollywood actress and an Indian hip-hop star. read more By Robert King HHS is withdrawing a controversial Trump-era rule that would have required the agency to review all existing regulations within five years. read more By Andrea Park The joint venture will develop a range of new kidney care tech, with a specific focus on at-home treatments that’ll make dialysis more easily accessible, offering an alternative to the typical schedule of in-clinic sessions three times a week. read more By Nick Paul Taylor There goes another one. After a who’s who of biopharmas failed the NIH’s inpatient COVID-19 study, NRx Pharmaceuticals has now flunked a related trial in severely ill patients, sending its share price down to the basement. read more By Dave Muoio "Every healthcare organization and every healthcare leader should be standing tall right now to advocate for action from Congress," said Northwell Health CEO Michael Dowling. read more By Kevin Dunleavy Those in the U.K. with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) finally have fully-funded treatment option. England’s National Institute for Health and Care Excellence (NICE) has signed off on Sanofi and Regeneron’s Libtayo for the tough-to-treat skin cancer, allowing patients in the U.K. fully funded access to the drug. read more By Nick Paul Taylor U.S. officials have arrested Enochian BioSciences co-founder Serhat Gümrükcü. The researcher is charged with conspiring to use interstate commerce facilities in the commission of murder-for-hire which resulted in a death. read more | 